Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Two Sigma Advisers LP lessened its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 41.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 51,000 shares of the company’s stock after selling 35,400 shares during the period. Two Sigma Advisers LP’s holdings in Compass Therapeutics were worth $74,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers raised its holdings in Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after purchasing an additional 3,822 shares in the last quarter. Invesco Ltd. increased its position in Compass Therapeutics by 11.3% during the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock worth $57,000 after purchasing an additional 4,018 shares during the period. Bank of New York Mellon Corp increased its position in Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares during the period. ProShare Advisors LLC raised its stake in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after buying an additional 9,451 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after buying an additional 11,326 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CMPX. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Monday, April 28th. Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, Jefferies Financial Group raised their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $13.13.

Insider Activity at Compass Therapeutics

In related news, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jonathan Anderman acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00% increase in their position. The disclosure for this purchase can be found here. 29.80% of the stock is owned by corporate insiders.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $2.50 on Monday. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The firm has a market capitalization of $345.71 million, a price-to-earnings ratio of -6.76 and a beta of 1.41. The stock’s fifty day moving average is $1.91 and its two-hundred day moving average is $2.16.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). As a group, sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.